Payment overview · 2025
General Payments
$3,818.60
195 reported records · 19 companies
Healthcare provider profile · identity verified
Mobin P Ghavami, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LODI, CA · NPI 1447239744
Verified facts
What the public records show
CMS Open Payments records show Mobin P Ghavami, M.D. received $3,818.60 in general payments during 2025 across 195 reported records.
Intra-Sana Laboratories accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $558.88 | 14.6% | 23 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $454.04 | 11.9% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $397.52 | 10.4% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $376.49 | 9.9% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $331.60 | 8.7% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $322.15 | 8.4% | 25 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $296.37 | 7.8% | 16 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $224.93 | 5.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.97 | 5.9% | 16 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.26 | 4.1% | 8 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $94.88 | 2.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.06 | 2.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.96 | 1.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.20 | 1.5% | 3 | 2025 |
| Curonix LLC | Unresolved — no canonical attribution shown | $50.69 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.58 | 1.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.10 | 0.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $23.26 | 0.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.66 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,818.60 | 195 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $558.88 | 23 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $558.88 | 23 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $558.88 | 23 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $454.04 | 30 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $447.03 | 18 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $296.37 | 16 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $296.37 | 16 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $296.37 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $275.81 | 8 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $224.93 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $203.36 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $196.72 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $193.95 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $173.37 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $165.71 | 13 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $158.26 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $153.16 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $150.80 | 13 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $94.88 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $94.06 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.96 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.20 | 3 | 2025 |
Source payment records
|
|||||
| PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A Normalized: pns freedom 4a permanent neurostimulator receiver kit channel a |
Device | Curonix LLC | $50.69 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $50.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.15 | 4 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $39.58 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 147 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 566 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 508 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 138 |
| Lisinopril | Lisinopril | 376 | 123 |
| Alprazolam | Alprazolam | 373 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 103 |
| Gabapentin | Gabapentin | 310 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 85 |
| Metformin Hcl | Metformin Hcl | 263 | 85 |
| Omeprazole | Omeprazole | 237 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 235 | 67 |
| Losartan Potassium | Losartan Potassium | 216 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 65 |
| Azithromycin | Azithromycin | 170 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 48 |
| Jardiance | Empagliflozin | 167 | 36 |
| Furosemide | Furosemide | 165 | 55 |
| Diclofenac Sodium | Diclofenac Sodium | 161 | 24 |
| Ozempic | Semaglutide | 147 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 28 |
| Baclofen | Baclofen | 140 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 45 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 116 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 31 |
| Potassium Chloride | Potassium Chloride | 116 | 37 |
| Pregabalin | Pregabalin | 116 | 44 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 113 | 103 |
| Prednisone | Prednisone | 107 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 18 |
| Glimepiride | Glimepiride | 98 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 15 |
| Ibuprofen | Ibuprofen | 94 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 31 |
| Simvastatin | Simvastatin | 91 | 34 |
| Linzess | Linaclotide | 88 | 23 |
| Allopurinol | Allopurinol | 87 | 23 |
| Trazodone Hcl | Trazodone Hcl | 83 | 24 |
| Breyna | Budesonide/Formoterol Fumarate | 80 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 79 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 77 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 15 |
| Carvedilol | Carvedilol | 71 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 40 |
| Lorazepam | Lorazepam | 70 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 22 |
| Bupropion Xl | Bupropion Hcl | 67 | 17 |
| Tramadol Hcl | Tramadol Hcl | 67 | 14 |
| Januvia | Sitagliptin Phosphate | 66 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 31 |
| Alendronate Sodium | Alendronate Sodium | 62 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 54 |
| Famotidine | Famotidine | 61 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 11 |
| Eliquis | Apixaban | 58 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 58 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Farxiga | Dapagliflozin Propanediol | 54 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 51 | 12 |
| Nystatin | Nystatin | 51 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Montelukast Sodium | Montelukast Sodium | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 17 |
| Estradiol | Estradiol | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Finasteride | Finasteride | 39 | 15 |
| Spironolactone | Spironolactone | 39 | 13 |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Naproxen | Naproxen | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Glipizide | Glipizide | 30 | 14 |
| Hydrocortisone | Hydrocortisone | 30 | 12 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | 14 |
| Fluconazole | Fluconazole | 28 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 11 |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 16 |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Primidone | Primidone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 18 |
| Atenolol | Atenolol | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Topiramate | Topiramate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,818.60 · 195 records | Intra-Sana Laboratories | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, GLYCATE, GVOKE HYPOPEN, IBSRELA, ID NOW INSTRUMENT, JARDIANCE, Korlym, LINZESS, MOUNJARO, NALOCET, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A, PROLATE, PURIFIED CORTROPHIN GEL, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, Symbravo, TANLOR, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error